individual monoclonal antibodies used to immunoextract CK-MM have little reactivity to CK-MB when used mdividually but seem to remove 15%-25% of CK-MB when used together. One could use a factor to correct for this. the IMPRES-MB-X with another version ofan inMA kit, which has greater precision than EMBRIA-CK, and astablished 5 U/L as the upper limit of non-MI for IMPRES-MB-X.
individual monoclonal antibodies used to immunoextract CK-MM have little reactivity to CK-MB when used mdividually but seem to remove 15%-25% of CK-MB when used together. One could use a factor to correct for this.
However, both CK-MB2 and CK-MB measurements are equally affected by this limitation, and consequently the ratio of the two, which is used for clinical assessment, is not affected. The specificity of the unique antibody that differentiates the CK-MB isoforrns was established by preparing mixtures of CK-MB2 and carboxypeptidase-converted CK-MB2. The theeretical values of fl these mixtures were 17%, 33%, 50%, 67%, and 83%; the values measured by IM-PRES-MB-X were 29%, 41%, 51%, 74%, and 80%, respectively.
The 
Wethereforeundertookthe following
study: (a) to evaluate the incidence of drug abuse in a pediatric outpatient population; and (b) to evaluate the currently suggested cutoff concentrations for positivity for cocaine, PCP, and cannabinoids tests-recommendations currently based on history rather than science (12)-and explore the implications of using lower cutoff limits.
The protocol ofthis study, conducted between January and July 1989 at Children's National Medical Center in Washington,
DC, was approved by the

Human Research
Committee (JEB). The Medical Center provides care for an ethnically and economically diverse population, and urinalysis is routinely requested on patients visiting any of our outpatient clinics. Leftover samplea obtained from patients ranging from ages three days to 18 years were screened for the presence of cocaine/ cocaine metabolite, PCP, and manmann by use of the ADx fluorescence polarization immunoassay technic (Abbott Laboratories, N. Chicago, IL). Three different cutoff concentrations were used for each drug (see Table 1 ). All positive samples were sent to American Medical Laboratories (Fairfx, VA 22030-0188) for gas-chromatographic/mass-spectrometric (GC/MS) confirmation. reported.
In the present study, the increase in false-positive results reported for cocaine/metabolite, PCP, and cannabinoids is 16%, 6%, and 0%, respectively. This higher rate of falsepositives also requires more extensive use of the GC/MS confirmatory method but greatly increases the number of patients detected to be "drug abusers."
The age distribution of results in this study shows the adolescent population (14-18 y) to be clearly most at risk for the abuse of one or more of the three drugs investigated. Of signifi-
however, is the high positive rate for benzoylecgonine in the 0 to 5-year-olds. Given the lower screening threshold for cocaine, the GC/MS confirmation ofpositive values for these children might reflect, in part, passive exposure.
As a result of this study, we recommend a more aggressive approach towards screening for drugs of abuse Clearly this is a very significant increase, with many legal and clinical implications for the patient population concerned. We recommend that the increased GC/MS workload is worth the effort for detecting more patients pealtive for one ofthe drugs ofabuse, a clear indication that they are being exposed.
However 
